Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study
Cancer Immunology, Immunotherapy · 2023-11 · 72 (11) · 3707-3716
DOI: 10.1007/s00262-023-03522-3 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 28.08.2023. Verfasst von Melissa Bersanelli und 27 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Hypovitaminosis D can have a negative prognostic impact in patients with cancer. Vitamin D has a demonstrated role in T-cell-mediated immune activation. We hypothesized that systematic vitamin D repletion could impact clinical outcomes in patients with cancer receiving immune-checkpoint inhibitors (ICIs).
Methods
We planned a prospective observational study (PROVIDENCE) to assess serum vitamin D levels in patients with advanced cancer receiving ICIs (cohort 1 at treatment initiation, cohort 2 during treatment) and the impact of systematic repletion on survival and toxicity outcomes. In an exploratory analysis, we compared the clinical outcomes of cohort 1 with a control cohort of patients followed at the participating centers who did not receive systematic vitamin D repletion.
Results
Overall, 164 patients were prospectively recruited in the PROVIDENCE study. In cohort 1, consisting of 101 patients with 94.1% hypovitaminosis (≤ 30 ng/ml) at baseline, adequate repletion with cholecalciferol was obtained in 70.1% at the three months re-assessment. Cohort 2 consisted of 63 patients assessed for vitamin D at a median time of 3.7 months since immunotherapy initiation, with no patients having adequate levels (> 30 ng/ml). Even in cohort 2, systematic supplementation led to adequate levels in 77.8% of patients at the three months re-assessment. Compared to a retrospective control group of 238 patients without systematic vitamin D repletion, PROVIDENCE cohort 1 showed longer overall survival (OS, p = 0.013), time to treatment failure (TTF, p = 0.017), and higher disease control rate (DCR, p = 0.016 ). The Inverse Probability of Treatment Weighing (IPTW) fitted multivariable Cox regression confirmed the significantly decreased risk of death (HR 0.55, 95%CI: 0.34–0.90) and treatment discontinuation (HR 0.61, 95%CI: 0.40–0.91) for patients from PROVIDENCE cohort 1 in comparison to the control cohort. In the context of longer treatment exposure, the cumulative incidence of any grade immune-related adverse events (irAEs) was higher in the PROVIDENCE cohort 1 compared to the control cohort. Nevertheless, patients from cohort 1 experienced a significantly decreased risk of all grade thyroid irAEs than the control cohort (OR 0.16, 95%CI: 0.03–0.85).
Conclusion
The PROVIDENCE study suggests the potential positive impact of early systematic vitamin D supplementation on outcomes of patients with advanced cancer receiving ICIs and support adequate repletion as a possible prophylaxis for thyroid irAEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
- Gruppo Oncologico Italiano Di Ricerca Clinica (GOIRC), Parma, Italy.
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Alvaro del Portillo N° 200, 00128, Rome, Italy. alessio.cortellini@gmail.com.
- Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK. alessio.cortellini@gmail.com.
- Department of Oncology, Università Politecnica Delle Marche-AOU Delle Marche, 60121, Ancona, Italy.
- Department of Medicine and Surgery, University of Parma, Parma, Italy.
Zitieren
APA
Bersanelli, M., Cortellini, A., Leonetti, A., Parisi, A., Tiseo, M., Bordi, P., Michiara, M., Bui, S., Cosenza, A., Ferri, L., Giudice, G. C., Testi, I., Rapacchi, E., Camisa, R., Vincenzi, B., Caruso, G., Rauti, A. N., Arturi, F., Tucci, M., …, & Buti, S. (2023). Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study. Cancer Immunology, Immunotherapy, 72(11), 3707-3716. https://doi.org/10.1007/s00262-023-03522-3
Vancouver
Bersanelli M, Cortellini A, Leonetti A, Parisi A, Tiseo M, Bordi P, et al. Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study. Cancer Immunology, Immunotherapy. 2023;72(11):3707-3716. doi:10.1007/s00262-023-03522-3
BibTeX
@article{Bersanelli2023,
author = {Bersanelli, Melissa and Cortellini, Alessio and Leonetti, Alessandro and Parisi, Alessandro and Tiseo, Marcello and Bordi, Paola and Michiara, Maria and Bui, Simona and Cosenza, Agnese and Ferri, Leonarda and Giudice, Giulia Claire and Testi, Irene and Rapacchi, Elena and Camisa, Roberta and Vincenzi, Bruno and Caruso, Giuseppe and Rauti, Antonio Natale and Arturi, Federica and Tucci, Marco and Santo, Valentina and Ricozzi, Valentina and Burtet, Vanessa and Sgargi, Paolo and Todeschini, Renata and Zustovich, Fable and Stucci, Luigia Stefania and Santini, Daniele and Buti, Sebastiano},
title = {Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
volume = {72},
number = {11},
pages = {3707--3716},
doi = {10.1007/s00262-023-03522-3}
}
EUVIMED